Piramal Healthcare acquires Alzheimer diagnosis product from Bayer

 

24.05.2012

 

Piramal Healthcare, a Mumbai-listed pharmaceutical company and one of the largest pharmaceutical manufacturers in the Indian market, has acquired the rights to Bayer Pharma's molecular imaging research and development portfolio, including Florbetaben, which is a pioneering molecular imaging product for the diagnosis of early Alzheimer's disease. The product has completed Phase 3 clinical trials, and is expected to be launched in the US and EU in 2013.

 

Piramal Healthcare was advised by Stephenson Harwood (team led by Andrew Edge) alongside Bär & Karrer. The Bär & Karrer team included Cédric Chapuis and Vanessa Déglise.

 

 

Suche in Deals & Cases